PARP1 and melanoma: Since Class I HDACs are often overexpressed in cancers and may contribute to those cancers’ response to therapy, we hypothesize that VPA—a histone deacetylase inhibitor, could sensitize melanomas to genotoxic agents such as dacarbazine (DTIC) administered alone or in combination with a PARP inhibitor.